Our News

See our press releases, presentations, and corporate information.

ournews-mobile (1)

Press Room

Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in The Lancet Neurology >

May 19, 2023

Neurocrine Biosciences Presents INGREZZA® (valbenazine) Capsules Data on Long-Term Improvements and Psychiatric Stability in Patients With Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder at the Schizophrenia International Research Society >

May 15, 2023

Neurocrine Biosciences Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023 >

May 12, 2023

Neurocrine Biosciences Reports First Quarter 2023 Financial Results >

May 3, 2023

Neurocrine Biosciences to Present at the Bank of America Securities 2023 Healthcare Conference >

May 2, 2023

Neurocrine Biosciences Supports the Mental Health Community During Tardive Dyskinesia Awareness Week >

May 1, 2023

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2023 Financial Results >

April 12, 2023

Resources

Resources

Our

Leadership

Investor

Information